Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

7(77.8%)

N/A

2(22.2%)

9Total

Phase 1(7)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06740786Not ApplicableNot Yet Recruiting

Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation

Role: collaborator

NCT06740539Not ApplicableNot Yet Recruiting

Atrial Fibrillation with Heart Failure with Preserved Ejection Fraction: Treatment Strategies-Catheter Ablation Vs. Anti-Atrial Arrhythmia Drugs

Role: collaborator

NCT02742727Phase 1Unknown

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Role: collaborator

NCT02892695Phase 1Unknown

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Role: collaborator

NCT02839954Phase 1Unknown

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Role: collaborator

NCT02944162Phase 1Unknown

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Role: collaborator

NCT02617134Phase 1Unknown

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

Role: collaborator

NCT02587689Phase 1Unknown

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Role: collaborator

NCT02819583Phase 1Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Role: collaborator

All 9 trials loaded